The extended Series B funding round will help Temedica further expand its offering of holistic insights into the care realities and patient journeys of millions of patients by combining health-related data
Temedica founders Gloria Seibert and Benjamin Friedrich. (Credit: Temedica GmbH)
Germany-based digital health company Temedica has secured €25m in an extended Series B funding round to expand its real-world insights ecosystem.
The extended financing round, which brings the company’s Series B funding to €42m, was led by existing investors MIG Capital, and a Munich-based family office.
Temedica intends to use the funding to further expand its ecosystem, which offers holistic insights into care realities and patient journeys.
The company’s unique ecosystem combines its real-world insights platform Permea and patient companion apps, to provide a complete understanding of patients’ care realities.
MIG Capital partner Boris Bernstein said: “Temedica is operating in a massively growing and highly attractive market. The newly developed real-world insights platform Permea provides pharmaceutical companies with a deep understanding of patients and their care in the real world, outside of clinical trials.
“Access to this unique 360° understanding of care realities has the potential to revolutionize our healthcare system as we know it. The team at Temedica is highly motivated and goal-oriented, and we are excited to work with them and continue our journey together.”
Temedica said that its ecosystem gathers data from varied sources, including registry data, sales data, insurance data, and patient experience data, along with patient-generated data from patient companion apps, with their consent.
The insights generated from connected data benefits all stakeholders, patients, healthcare professionals, clinics, research institutions, pharmaceutical companies, and pharmacies.
The company will send the information and insights back to patients, through its patient companion apps, to help patients get an individualised understanding of their disease.
Temedica stated that all its activities meet the highest ethical and technical standards for privacy and data protection, and complies with Europe Union (EU)’s General Data Protection Regulation (GDPR) requirements.
The health insights company is backed by a consortium of investors with experience in the biopharmaceutical industry, including the founding investors of BioNTech.
Temedica founder and chief executive officer Gloria Seibert said: “Temedica’s vision is to make a pioneering contribution to the development of personalized medicine by linking health-relevant data to new, evidence-based insights.
“We are convinced that big data sets and completely new types of data play a key role in this, such as patient-generated data from large populations outside of classic clinical trials.
“These enable a completely new knowledge and understanding of diseases and their actual courses. I am very pleased that our investors share this vision and accompany and support us as we continue to expand the Temedica ecosystem.”